Cowen raised its price target on Biogen (NASDAQ: BIIB) to $408.00 (from $338.00) while maintaining an Outperform rating.

Analyst Eric Schmidt highlighted that the MS franchise is steady while Spinraza sales were strong as the drug's ex-U.S. launch has accelerated.